How to manage an isolated elevated PTH?

Annales d'Endocrinologie

Volumn 76, Issue 2, 2015, Pages 134-141

  Souberbielle, Jean Claude ^a   Cavalier, Etienne ^b   Cormier, Catherine ^c  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c Institut Cochin   (France)

Author keywords

Hypercalciuria; Parathyroid hormone; Primary hyperparathyroidism; Secondary hyperparathyroidism; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; LITHIUM SALT; LOOP DIURETIC AGENT; MAGNESIUM; PARATHYROID HORMONE; PHOSPHATE; RALOXIFENE; THIAZIDE DIURETIC AGENT; VITAMIN D;

ARTICLE; BONE DISEASE; BONE METABOLISM; CALCIUM BLOOD LEVEL; CALCIUM DEFICIENCY; CALCIUM INTAKE; CALCIUM LOAD TEST; CALCIUM METABOLISM; CALCIUM URINE LEVEL; CLINICAL ASSESSMENT TOOL; CLINICAL PRACTICE; DIAGNOSTIC TEST ACCURACY STUDY; DRUG MEGADOSE; DRUG TOLERABILITY; GLOMERULUS FILTRATION RATE; HUMAN; HUNGRY BONE SYNDROME; HYPERCALCEMIA; HYPERCALCIURIA; HYPERPARATHYROIDISM; HYPOMAGNESEMIA; KIDNEY DISEASE; KIDNEY FUNCTION; MALABSORPTION; NORMOCALCEMIC PRIMARY HYPERPARATHYROIDISM; OSTEOLYSIS; PARATHYROID HORMONE BLOOD LEVEL; PH; PHOSPHATE BLOOD LEVEL; PHOSPHATE METABOLISM; PHOSPHATURIA; POSTOPERATIVE COMPLICATION; PSEUDOHYPOPARATHYROIDISM; QUESTIONNAIRE; REFERENCE VALUE; RENAL CALCIUM LEAK; SENSITIVITY ANALYSIS; VITAMIN D DEFICIENCY; BLOOD; HYPERPARATHYROIDISM, PRIMARY; HYPERPARATHYROIDISM, SECONDARY;

CALCIUM; HUMANS; HYPERCALCIURIA; HYPERPARATHYROIDISM; HYPERPARATHYROIDISM, PRIMARY; HYPERPARATHYROIDISM, SECONDARY; PARATHYROID HORMONE;

EID: 84929703820     PISSN: 00034266     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ando.2015.03.005     Document Type: Article

References (42)

1. Touvier M., Deschasaux M., Montourcy M., Sutton A., Charnuax N., Kess-Guyot E., et al. Interpretation of plasma PTH concentrations according to 25OHD status, gender, age, weight status, and calcium intake: importance of the reference values. J Clin Endocrinol Metab 2014, 99:1196-1203.
2. Björkman M., Sorva A., Tilvis R. Responses of parathyroid hormone to vitamin D supplementation: a systematic review of clinical trials. Arch Gerontol Geriatrics 2009, 48:160-166.
3. Eastell R., Arnold A., Brandi M.L., et al. Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 2009, 94:340-350.
4. Bilezikian J., Brandi M.L., Eastell R., et al. Guidelines for the management of asymptomatic ptrimary hyperparathyroidism: summary statement from the fourth international workshop. J Clin Endocrinol metab 2014, 99:3561-3569.
5. Nussbaum S., Zahradnik R., Lavigne J., Brennan G., Nozawa-Ung K., Kim L., et al. Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. Clin Chem 1987, 33:1364-1367.
6. Blind E., Schmidt-Gayk H., Scharla S., Flentje D., Fischer S., Göhring U., et al. Two-site assay of intact parathyroid hormone in the investigation of primary hyperparathyroidism and other disorders of calcium metabolism compared with a mid-region assay. J Clin Endocrinol Metab 1988, 67:353-360.
7. Endres D., Villanueva R., Sharp C., Singer F. Immunochemiluminometric and immunoradiometric determinations of intact and total immunoreactive parathyrin: performance in the differential diagnosis of hypercalcemia and hypoparathyroidism. Clin Chem 1991, 37:162-168.
8. Ratcliffe W., heath D., Ryan M., Jones S. Performance and diagnostic application of a two-site immunometric assay for parathyrin in serum. Clin Chem 1989, 35:1957-1961.
9. Gao P., Scheibel S., D'Amour P., John M., Rao S., Schmidt-Gayk H., et al. Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1-84: implication for improvement of accurate assesment of parathyroid function. J Bone Miner Res 2001, 16:605-614.
10. Souberbielle J.C., Cormier C., Kindermans C., Gao P., Cantor T., Forette F., et al. Vitamin D status and redefining serum parathyroid hormone reference range. J Clin Endocrinol Metab 2001, 86:3086-3090.
11. Souberbielle J.C., Fayol V., Sault C., Lawson-Body E., Kahan A., Cormier A. Assay-specific decision limits for two new automated parathyroid hormone and 25-hydroxyvitamin D assays. Clin Chem 2005, 51:395-400.
12. Cavalier E., Delanaye P., Vranken L., Bekaert A.C., Carlisi A., Chapelle J.P., et al. Interpretation of serum PTH concentrations with different kits in dialysis patients according to the KDIGO guidelines: importance of the reference (normal) values. Nephrol Dial Transplant 2012, 27:1950-1956.
13. Djennane M., Lebbah S., Roux C., Djoudi H., Cavalier E., Souberbielle J.C. Vitamin D status of schoolchildren in Northern Algeria, seasonal variations and determinants of vitamin D deficiency. Osteoporos Int 2014, 25:1493-1502.
14. Ross C., Manson J.E., Abrams S., et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab 2011, 96:53-58.
15. Holick M., Binkley N., Bischoff-Ferrari H., et al. Evaluation, treatment and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011, 96:1911-1930.
16. Aloia J., Talwar S., Pollack S., et al. Optimal vitamin D status and serum parathyroid hormone concentrations in African American women. Am J Clin Nutr 2006, 84:602-609.
17. Okazaki R., Sugimoto T., Kaji H., et al. Vitamin D insufficiency defined by serum 25-hydroxyvitamin D and parathyroid hormone before and after oral vitamin D3 supplementation load in Japanese patients. J Bone Miner Metab 2011, 29:103-110.
18. KDIGO.Work Group C.-M. Clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone disorder (CKD-MBD). Kidney Int 2009, 76(Suppl.113):S1-S130.
19. Rejnmark L., Vestergaard P., Heickendorf L., Mosekilde L. Determinants of plasma PTH and their implication for defining a reference interval. Clin Endocrinol (Oxford) 2011, 74:37-43.
20. Bell N.H., Greene A., Epstein S., Oexmann M.J., Shaw S., Shary J.R. Evidence for alteration of the vitamin D-endocrine system in blacks. J Clin Invest 1985, 76:470-473.
21. Quesada J.M., Coopmans W., Ruiz B., Aljam P., Jans I., Bouillon R. Influence of vitamin D on parathyroid hormone in the elderly. J Clin Endocrinol Metab 1992, 75:494-501.
22. Souberbielle J.C., Lawson-Body E., Hammadi B., Sarfati E., Kahan A., Cormier C. The use in clinical practice of parathyroid hormone normative values established in vitamin D-sufficient subjects. J Clin Endocrinol Metab 2003, 88:3501-3504.
23. Gauci C., Moranne O., Fouqueray B., de la Faille R., Maruani G., Haymann J.P., et al. Pitfalls of measuring total blood calcium in patients with CKD. J Am Soc Nephrol 2008, 19:1592-1598.
24. Ong G., Walsh J., Stuckey B., et al. The importance of measuring ionized calcium in characterizing calcium status and diagnosing primary hyperparathyroidism. J Clin Endocrinol Metab 2012, 97:3138-3145.
25. Heaney R.P., Recker R., Ryan R. Urinary calcium in perimenopausal women: normative values. Osteoporos Int 1999, 9:13-18.
26. Cavalier E., Rozet E., Gadisseur R., Carlisi A., Monge M., Chapelle J.P., et al. Measurement uncertainty of 25-OH vitamin D determination with different commercially available kits: impact on the clinical cut-offs. Osteoporos Int 2010, 21:1047-1051.
27. KDIGO Clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int 2009, 79:S1-S130.
28. Yamamoto M., Yamaguchi T., Yamauchi M., Yano S., Sugimoto T. Acute-onset hypomagnesemia-induced hypocalcemia caused by the refractoriness of bones and renal tubules to parathyroid hormone. J Bone Miner Metab 2011, 29:752-755.
29. Mantovani G. Pseudohypoparathyroidism: diagnosis and treatment. J Clin Endocrinol metab 2011, 96:3020-3030.
30. Cusano N., Siverberg S., Bilezikian J. Normocalcemic primary hyperparathyroidism. J Clin Densitometry. 2013, 16:33-39.
31. Lowe H., McMahon D.J., Rubin M., et al. Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. J Clin Endocrinol Metab 2007, 92:3001-3005.
32. Maruani G., Hertig A., Paillard M., Houillier P. Normocalcemic primary hyperparathyroidism: evidence for a generalized target-tissue resistance to parathyroid hormone. J Clin Endocrinol Metab 2003, 88:4641-4648.
33. Garcia-MartinA, Reyes-Garcia R., Munoz-Torres M. Normocalcemic primary hyperparathyroidism: one year follow-up in one hundred postmenopausal women. Endocrine 2012, 42:764-766.
34. Cusano N., Maalouf N., Wang P., Zhang C., Cremers S., Haney E., et al. Normocalcemic hyperparathyroidism and hypoparathyroidism in two community-based non-referral populations. J Clin Endocrinol Metab 2013, 98:2734-2741.
35. Koumakis E., Souberbielle J.C., Sarfati E., Meunier M., Maury E., Gallimard E., et al. Bone mineral density evolution after successful parathyroidectomy in patients with normocalcemic primary hyperparathyroidism. J Clin Endocrinol Metab 2013, 98:3213-3220.
36. Eisner B., Ahn J., Stoller M. Differentiating primary from secondary hyperparathyroidism in stone patients: the "thiazide challenge". J Endourol 2009, 23:191-192.
37. Bevilacqua M., Dominguez L., Righini V., Valdes V., Vago T., Leopaldi E., et al. Dissimilar PTH, gastrinn and calcitonin responses to oral calcium and peptones in hypocalciuric hypercalcemia, primary hyperparathyroidism, and normal subjects: a useful tool for differential diagnosis. J Bone Miner Res 2006, 21:406-412.
38. Gomes S.A., Lage A., Lazareti-Castro M., Vieira J.G.H., Heilberg L.P. Response to an oral calcium load in nephrolithiasis patients with fluctuating parathyroid hormone and ionized calcium levels. Braz J Med Biol Res 2004, 37:1379-1388.
39. Monchik J.M., Lamberton R.P., Roth U. Role of the oral calcium-loading test with measurement of intact parathyroid hormone in the diagnosis of symptomatic subtle primary hyperparathyroidism. Surgery 1992, 112:1103-1109.
40. McHenry C.R., Rosen I.B., Walfish P.G., Pollard A. Oral calcium load test: diagnostic and physiologic complications in hyperparathyroidism. Surgery 1990, 108:1026-1031.
41. Cadiot G., Houillier P., Alouch A., Paillard M., Mignon M. Oral calcium tolerance test in the early diagnosis of primary hyperparathyroidism and multiple endocrine neoplasia typ1 in patients with the Zollinger-Ellison syndrome. Gut 1996, 39:273-278.
42. Lepage R., Whittom S., Bertrand S., Bahsali G., D'Amour P. Superiority of dynamic over static reference intervals for intac, midmolecule, and C-terminal parathyrin in evaluating calcemic disorders. Clin Chem 1992, 38:2129-2135.